Orlistat for the Treatment of Type I Hyperlipoproteinemia (NCT02767531) | Clinical Trial Compass
CompletedPhase 2
Orlistat for the Treatment of Type I Hyperlipoproteinemia
United States2 participantsStarted 2015-12
Plain-language summary
Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the only effective therapy available is an extremely low fat diet. This diet is exceedingly difficult to follow, and despite adherence, many patients still have chylomicronemia and develop acute pancreatitis.
Specific Aim: To determine the efficacy of a gastric and pancreatic lipase inhibitor, Orlistat, in reducing serum triglyceride levels in patients with T1HLP.
Who can participate
Age range8 Years – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Type I hyperlipoproteinemia
✓. Fasting serum triglyceride levels of greater than 1000 mg/dL
✓. Age \> 8 years
Exclusion criteria
✕. Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIVprotease inhibitors, retinoic acid derivatives and interferons
✕. Pregnant or lactating women
✕. Significant liver disease (elevated transaminases \> 2 times upper limit of normal) Alcohol abuse (\> 7 drinks or 84 g per week for women and \> 14 drinks or 168 g per week for men)
✕. Severe anemia (hematocrit \< 24%)
✕. Drug use (cocaine, marijuana, LSD, etc.)
✕. Major surgery in the past three months
✕. Congestive heart failure
What they're measuring
1
Fasting Serum Triglycerides
Timeframe: 3 days
Trial details
NCT IDNCT02767531
SponsorUniversity of Texas Southwestern Medical Center